HTB homepage • Conference reports • Articles by subject • Subscribe 12 March 2019 Contents Editorial 13 March 2019: vol 20 no 3 – first CROI reports Supplements i-Base Fit for Purpose report launched at CROI 2019 Conference reports Conference on Retroviruses and Opportunistic Infections (CROI 2019): early reports UK patient likely to be the second person cured of HIV: two further cases at CROI 2019 of HIV remission after allogenic stem cell transplants Phase 3 results with dual therapy cabotegravir/rilpivirine long-acting injections: ATLAS and FLAIR studies Viral reservoir can explain persistent low level viraemia with good adherence on ART Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2 Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz New option for PrEP – TAF/FTC is non-inferior to TDF/FTC: results of phase 3 DISCOVER study Dolutegravir can be given with 3HP to prevent TB without dose adjustment Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity Shared housing compared to living alone: higher CD4, lower viral load and reduced inflammation in macaques Selected webcasts at CROI 2019 Pre-CROI Community HIV Cure Workshop 2019 Research studies US requires informed consent forms for clinical studies to be posted online On the web Reports from cure strategies meetings PDFs 13 March 2019 vol 20 no 3 HTB homepage • Conference reports • Articles by subject • Subscribe
